Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Ravenna
Clinical trial register · Italy

Clinical Trials in Ravenna, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6791 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:19 UTC
6791
Studies in scope
all four open statuses
4079
Recruiting now
open to new participants
1019
Lead sponsors
across recruiting studies
Top sites
Milan 2846 Bologna 1303 Roma 1272 Naples 983 Rome 968
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Janssen Research & Development, LLC9 Hoffmann-La Roche7 Bristol-Myers Squibb6 AstraZeneca5 Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS5
Site location
Milan2846 Bologna1303 Roma1272 Naples983 Rome968
All 489 locations
Target enrolment
to

Trials with a site in Ravenna

119 of 6791 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Recruiting
Bristol-Myers Squibb
Phase 2
160
Misterbianco, Bari, Bergamo, Milan, Ravenna, Rozzano (MI)
2026-09-10
Recruiting
Novo Nordisk A/S
Phase 3
1,778
Chieti, Catanzaro, Naples, Ravenna, Chiavari, Milan, Roma, Lucca
2026-08-24
Recruiting
AstraZeneca
Phase 3
4,500
Bologna, Catania, Chieti, Florence, Latina, Milan, Pisa, Ravenna
2026-06-29
Recruiting
AstraZeneca
Phase 2
80
Meldola, Milan, Padua, Ravenna, Rome, Torino
2026-06-04
Recruiting
University Hospital of Ferrara
Not applicable
1,612
Andria, Arezzo, Bologna, Ferrara, Grosseto, L’Aquila, Mirano, Ravenna
2026-05-25
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
118
Candiolo, Meldola, Ravenna
2026-03-31
Recruiting
Liaquat University of Medical & Health Sciences
Not applicable
132
Forlì, Ravenna, Rome, Brescia, Pavia, Turin, Catania, Florence
2026-03-23
Recruiting
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
NCT07219459Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
DrugsVisugromab RDE·Opdivo·Lenvatinib·Nivolumab
CatalYm GmbH
Phase 2
104
Bologna, Milan, Ravenna
2026-03-19
Recruiting
Bristol-Myers Squibb
Phase 3
850
Naples, Ravenna, Aviano, Orbassano, Rome, Milan, Parma
2026-03-16
Recruiting
Genmab
Phase 2
240
Candiolo, Meldola, Orbassano, Ravenna, Roma
2026-01-30
Recruiting
AstraZeneca
Phase 1/2
84
Bologna, Ravenna
2026-01-09
Recruiting
Bristol-Myers Squibb
Phase 2/3
590
Naples, Ravenna, Aviano, Orbassano, Siena, Perugia, Bologna, Milan
2026-01-02
Recruiting
Merck Sharp & Dohme LLC
Phase 2
180
Ravenna, Milan, Roma
2025-12-12
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
Ancona, Candiolo, Meldola, Ravenna, Roma, Verona
2025-11-30
Recruiting
Bristol-Myers Squibb
Phase 2/3
500
Ravenna, Aviano, Orbassano, Candiolo, Avellino, Milan, Naples, Parma
2025-11-05
Recruiting
Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.
NCT07407465Colorectal Cancer, Colorectal Adenocarcinoma, Rectal Adenocarcinoma, Rectal Cancer, Adenocarcinoma
DrugsTrastuzumab deruxtecan·Capecitabine·Bevacizumab
Gruppo Oncologico del Nord-Ovest
Phase 2
42
Bari, Florence, Milan, Ravenna, Rozzano, Tricase, Modena, Roma
2025-10-20
Recruiting
Nurix Therapeutics, Inc.
Phase 2
100
Alessandria, Bologna, Milan, Ravenna
2025-10-15
Active, closed
A New Crowding Indicator in the Emergency Department
NCT07111624Emergency Department, Crowding
Mario Negri Institute for Pharmacological Research
Observational
828
Brescia, Genova, Ravenna, Roma, Cirié, Orbassano, Vercelli, Alessandria
2025-10-15
Recruiting
CatalYm GmbH
Phase 2
131
Forlì, Aviano, Rome, Ravenna
2025-10-07
Recruiting
Pfizer
Phase 3
1,000
Meldola, Ravenna, Rozzano, Orbassano, Rome, Milan, Novara, Padova
2025-09-28
Recruiting
Kura Oncology, Inc.
Phase 3
1,300
Bologna, Ravenna, Trieste, Brescia, Ascoli Piceno, Perugia
2025-09-26
Recruiting
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
NCT07169734Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer, Intrahepatic Cholangiocarcinoma
Alentis Therapeutics AG
Phase 1/2
180
Milan, Ravenna, Rossano, Siena
2025-08-26
Recruiting
CatalYm GmbH
Phase 2
107
Meldola, Milan, Aviano, Ravenna, Rome
2025-08-01
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
DrugsNeladalkib·Alectinib
Nuvalent Inc.
Phase 3
450
Ancona, Bari, Meldola, Milan, Monza, Pisa, Ravenna, Roma
2025-07-17
Recruiting
Merck Sharp & Dohme LLC
Phase 3
477
Monserrato, Milan, Naples, Padova, Ravenna, Verona
2025-07-16
Recruiting
Hoffmann-La Roche
Observational
700
Lecce, Naples, Modena, Ravenna, Rome, Genoa, Bergamo, Milan
2025-07-15
Recruiting
Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
NCT05815927Oligometastatic Squamous Cell Carcinoma of the Head and Neck
DrugPembrolizumab
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
200
Bologna, Cuneo, Florence, Milan, Naples, Ravenna, Rome
2025-05-23
Recruiting
Moleculin Biotech, Inc.
Phase 2/3
312
Bologna, Florence, Ravenna, Roma
2025-03-12
Recruiting
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 3
339
Bologna, Genova, Palermo, Pescara, Perugia, Ravenna, Roma, Torino
2025-02-27
Active, closed
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2
136
Legnano, Ravenna, Udine
2025-01-14
Recruiting
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
NCT06747585Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma
Alentis Therapeutics AG
Phase 1/2
170
Milan, Ravenna, Roma, Verona
2024-12-16
Recruiting
Janssen Research & Development, LLC
Phase 2
480
Orbassano, Padova, Ravenna, Roma, Rozzano
2024-12-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
680
Catanzaro, Ravenna, Rome, Milan, Naples, Padova, Verona
2024-10-21
Recruiting
argenx
Phase 3
69
Bassano del Grappa, Florence, Milan, Novara, Ravenna, Reggio Emilia, Torino, Trieste
2024-10-18
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Bari, Ravenna, Monza, Milan, Naples, Rome, Peschiera del Garda, Bergamo
2024-10-07
Recruiting
Regeneron Pharmaceuticals
Phase 2
116
Meldola, Genoa, Milan, Alessandria, Ascoli Piceno, Pavia, Ravenna
2024-09-16
Active, closed
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
NCT06430866Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
DrugsABP 234·Pembrolizumab
Amgen
Phase 3
163
Cona, Cuneo, Florence, Lucca, Monserrato, Naples, Peschiera del Garda, Ravenna
2024-09-12
Active, closed
Amgen
Phase 3
315
Cona, Cremona, Milan, Naples, Ravenna, Sondrio, Terni
2024-09-09
Active, closed
Celgene
Phase 3
850
Ravenna, Rome, Palermo, Novara
2024-06-19
Recruiting
Merck Sharp & Dohme LLC
Phase 3
348
Naples, Ravenna, Aviano, Rome, Milan, Livorno, Padova
2024-05-24
Recruiting
AstraZeneca
Phase 3
675
Bergamo, Genoa, Milan, Monza, Padova, Pavia, Ravenna, Roma
2024-04-11
Active, closed
Janssen Research & Development, LLC
Phase 3
272
Arezzo, Milan, Province of Macerata, Ravenna, Roma, Rozzano, Torino
2024-04-09
Active, closed
Byondis B.V.
Phase 1
17
Brescia, Candiolo, Milan, Ravenna
2024-03-04
Recruiting
Kura Oncology, Inc.
Phase 1
171
Bologna, Ravenna, Roma
2024-02-22
Recruiting
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2
89
Milan, Padova, Ravenna, Rozzano, Udine
2024-01-22
Recruiting
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
NCT06162221Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
DrugsElironrasib·RMC-9805·Cetuximab·Pemetrexed
Revolution Medicines, Inc.
Phase 1/2
616
Meldola, Milan, Orbassano, Ravenna, Rome
2024-01-18
Recruiting
Ryvu Therapeutics SA
Phase 2
98
Meldola, Ancona, Bologna, Brescia, Lecce, Ravenna, Roma, Rozzano
2024-01-05
Recruiting
Bristol-Myers Squibb
Phase 1/2
460
Bologna, Brescia, Milan, Pisa, Ravenna, Roma, Verona
2023-12-29
Active, closed
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
NCT05973773Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
DrugZipalertinib
Taiho Oncology, Inc.
Phase 3
285
Meldola, Genova, Milan, Modena, Pavia, Ravenna, Roma, Verona
2023-12-18
Recruiting
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
NCT06128551Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
DrugsElironrasib·Cetuximab
Revolution Medicines, Inc.
Phase 1/2
534
Verona, Ancona, Aviano, Meldola, Milan, Naples, Orbassano, Ravenna
2023-11-14
Active, closed
AstraZeneca
Phase 3
895
Bari, Bergamo, Milan, Padova, Parma, Pavia, Ravenna, Roma
2023-10-24
Recruiting
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
NCT06051409Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
DrugOlverembatinib
Ascentage Pharma Group Inc.
Phase 3
350
Bologna, Meldola, Milan, Monza, Ravenna, Roma, Torino, Varese
2023-08-31
Recruiting
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
DrugZipalertinib
Taiho Oncology, Inc.
Phase 2
220
Florence, Meldola, Cremona, Milan, Parma, Ravenna
2023-07-31
Active, closed
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2
78
Florence, Meldola, Perugia, Ravenna, Rimini, Roma, Siena
2023-07-21
Active, closed
Hoffmann-La Roche
Phase 2
83
Ravenna, Milan
2023-07-18
Recruiting
Hoffmann-La Roche
Phase 3
420
Caserta, Meldola, Ravenna, Aviano, Milan, Alessandria, Turin, Misterbianco (CT)
2023-06-07
Recruiting
AUSL Romagna Rimini
Not applicable
200
Acquaviva delle Fonti, Forlì, Ravenna
2023-05-01
Recruiting
Eli Lilly and Company
Phase 1/2
880
Alessandria, Brescia, Milan, Monza, Pisa, Ravenna, Roma, Verona
2023-04-17
Recruiting
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2
60
Meldola, Monza, Pesaro, Bari, Bologna, Naples, Padova, Ravenna
2023-03-27
Active, closed
Janssen Research & Development, LLC
Phase 3
1,135
Acquaviva delle Fonti, Asti, Avellino, Castelfranco Veneto, Milan, Naples, Ravenna, Rome
2023-03-23
Recruiting
Montreal Heart Institute
Phase 3
10,000
Foggia, Acquaviva delle Fonti, Ferrara, Ravenna, Milan, Turin, Ancona, Florence
2022-12-21
Active, closed
Janssen Research & Development, LLC
Phase 1/2
57
Milan, Naples, Padova, Ravenna, Rome
2022-12-13
Active, closed
Mirati Therapeutics Inc.
Phase 2
90
Avellino, Casale Monferrato, Florence, Milan, Orbassano, Ravenna, Roma
2022-11-22
Recruiting
Pfizer
Phase 3
1,060
Meldola (Fc), Piacenza, Ravenna, San Giovanni Rotondo, Aviano, Monza, Turin, Palermo
2022-11-10
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Bari, Bologna, Milan, Orbassano, Padova, Ravenna, Roma, Rome
2022-08-05
Active, closed
Incyte Corporation
Phase 1/2
53
Ravenna, Milan, Pavia, Monza, Candiolo, Pisa, Perugia
2022-07-19
Active, closed
Cogent Biosciences, Inc.
Phase 2
237
Bologna, Catania, Florence, Pavia, Ravenna
2022-06-27
Recruiting
Nuvalent Inc.
Phase 1/2
840
Ancona, Bari, Milan, Padova, Ravenna, Rome
2022-06-09
Recruiting
Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera
NCT06516406Myelofibrosis, Primary Myelofibrosis, Secondary Myelofibrosis
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Observational
1,055
Cosenza, Reggio Calabria, Naples, Bologna, Ferrara, Parma, Piacenza, Ravenna
2022-05-06
Active, closed
AUSL Romagna Rimini
Observational
63,500
Ravenna
2022-04-27
Recruiting
Azienda Ospedaliero-Universitaria di Parma
Not applicable
100
Meldola, Bologna, Ferrara, Parma, Piacenza, Ravenna, Reggio Emilia, Rimini
2022-03-01
Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
DrugsAzoles·Gilteritinib·Azacitidine·Venetoclax
Sumitomo Pharma America, Inc.
Phase 1/2
606
Bologna, Busto Arsizio, Genoa, Meldola, Padua, Perugia, Ravenna, Rome
2022-02-28
Active, closed
Unraveling the Role of Extracellular Vesicles-driven Senescence in Myeloproliferative Neoplasms
NCT06798805Essential Thrombocythemia (ET), Myelofibrosis (MF), Polycythemia Vera (PV)
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Observational
110
Bologna, Brescia, Meldola, Ravenna, Reggio Emilia
2022-02-15
Recruiting
Nuvalent Inc.
Phase 1/2
359
Ancona, Bari, Milan, Padova, Ravenna, Rome
2022-01-04
Recruiting
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
NCT05176483Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor
DrugsZanzalintinib·Relatlimab·Yervoy·Ipilimumab
Exelixis
Phase 1
1,394
Ancona, Bologna, Florence, Milan, Naples, Ravenna
2021-12-14
Active, closed
Hoffmann-La Roche
Phase 3
660
Ravenna, Genoa, Milan, Torrette Di Ancona
2021-11-18
Active, closed
Janssen Research & Development, LLC
Phase 3
776
Aviano, Meldola, Milan, Parma, Ravenna, Roma, Verona
2021-11-17
Active, closed
Hoffmann-La Roche
Phase 3
478
Bologna, Ravenna, Palermo, Ancona, Florence, Padova
2021-10-27
Active, closed
International Extranodal Lymphoma Study Group (IELSG)
Phase 2
26
Brescia, Milan, Novara, Ravenna, Reggio Emilia, Varese
2021-10-20
Active, closed
University Hospital of Ferrara
Not applicable
249
Ferrara, Bologna, Forlì, Palermo, Ravenna, Rimini, Trieste
2021-06-03
Active, closed
Geron Corporation
Phase 3
327
Alessandria, Bologna, Cona, Florence, Genova, Milan, Ravenna, Reggio Calabria
2021-04-12
Active, closed
Loxo Oncology, Inc.
Phase 3
500
Alessandria, Meldola, Ravenna, Milan, Bologna, Genova, Palermo, Potenza
2021-04-08
Active, closed
Genmab
Phase 3
483
Bari, Bergamo, Brescia, Meldola, Milan, Novara, Pavia, Ravenna
2021-01-13
Active, closed
Janssen Research & Development, LLC
Phase 3
308
Bologna, Catania, Meldola, Milan, Monza, Ravenna, Roma, Rozzano
2020-10-13
Active, closed
Hoffmann-La Roche
Phase 3
190
Ravenna, Rome, Milan, Turin, Florence
2020-09-30
Active, closed
Janssen Research & Development, LLC
Phase 3
1,074
Avellino, Catania, Meldola, Milan, Monza, Naples, Orbassano, Ravenna
2020-09-30
Recruiting
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Observational
250
Meldola, Ravenna
2020-09-22
Active, closed
ADC Therapeutics S.A.
Phase 3
440
Udine, Brescia, Florence, Foggia, Meldola, Milan, Pavia, Ravenna
2020-09-16
Recruiting
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
NCT04256317Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia
DrugsVenclexta·Azacitidine·Venetoclax
Taiho Oncology, Inc.
Phase 2/3
316
Ravenna, Florence, Torino, Bologna, Milan, Novara, Roma
2020-05-21
Recruiting
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Observational
300
Meldola, Ravenna, Bologna, Rimini
2020-05-14
Recruiting
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Observational
300
Cesena, Forlì, Bologna, Ravenna, Rimini
2020-04-21
Active, closed
GlaxoSmithKline
Phase 3
325
Bologna, Brescia, Catanzaro, Milan, Pavia, Perugia, Ravenna, Roma
2020-04-02
Active, closed
BeOne Medicines
Phase 1
437
Milan, Perugia, Ravenna, Roma, Verona
2020-03-24
Active, closed
Eli Lilly and Company
Phase 3
261
Naples, Ravenna, Aviano, Rome, Monza, Milan, Rozzano, Orbassano
2020-02-17
Active, closed
BeOne Medicines
Phase 3
955
Bologna, Meldola, Milan, Modena, Novara, Ravenna, Roma, Terni
2020-01-16
Active, closed
Takeda
Phase 3
354
Naples, Meldola, Milan, Orbassano, Aviano, Pisa, Parma, Ravenna
2020-01-10
Active, closed
Cold Agglutinin Disease Real World Evidence Registry
NCT05791708Cold Agglutinin Disease (CAD), Cold Agglutinin Syndrome (CAS)
RECORDATI GROUP
Observational
429
Brescia, Campobasso, Novara, Palermo, Pavia, Ravenna, Reggio Calabria, Roma
2019-12-12
Active, closed
Regeneron Pharmaceuticals
Phase 2
515
Milan, Bologna, Livorno, Novara, Perugia, Ravenna, Reggio Emilia, Varese
2019-11-13
Active, closed
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
NCT04036682Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
DrugZipalertinib
Cullinan Therapeutics Inc.
Phase 1/2
284
Careggi, Marche, Meldola, Milan, Modena, Monza, Ravenna
2019-10-31
Recruiting
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Observational
60
Meldola, Ravenna, Rimini
2019-10-23
Recruiting
ALFAOMEGA Master Observational Trial
NCT04120935Colorectal Cancer
IFOM ETS - The AIRC Institute of Molecular Oncology
Observational
3,000
Biella, Milan, Padova, Perugia, Pisa, Ravenna, Candiolo, Orbassano
2019-10-15
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
466
Torrette, Bologna, Rome, Faenza, Lugo, Cattolica, Milan, Ravenna
2019-10-02
Active, closed
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
NCT04067336Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia
DrugsZiftomenib·Itraconazole·Midazolam
Kura Oncology, Inc.
Phase 1/2
263
Bologna, Meldola, Ravenna, Roma
2019-09-12
Active, closed
Janssen Research & Development, LLC
Phase 1
701
Milan, Monza, Naples, Ravenna
2019-09-04
Active, closed
BeOne Medicines
Phase 3
510
Alessandria, Bologna, Genova, Milan, Novara, Palermo, Pisa, Ravenna
2019-08-20
Active, closed
Consorzio Futuro in Ricerca
Not applicable
1,445
Bologna, Ferrara, Cotignola, Ravenna, Reggio Emilia, Rimini, Agrigento, Caserta
2019-07-15
Active, closed
Dizal Pharmaceuticals
Phase 1/2
315
Aviano, Catania, Florence, Meldola, Milan, Parma, Ravenna, Reggio Emilia
2019-07-09
Active, closed
Acerta Pharma BV
Phase 3
984
Meldola, Milan, Novara, Ravenna, Torino
2019-02-25
Active, closed
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
NCT03485209Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
DrugsTisotumab Vedotin·Tivdak·Keytruda·Cisplatin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
350
Meldola (Fc), Ravenna, Meldola (FC), Rome, Brescia, Milan, Cattolica, Rimini
2018-06-25
Active, closed
MedImmune LLC
Phase 1
400
Meldola, Naples, Ravenna, Roma
2018-04-24
Active, closed
BeiGene
Phase 3
590
Brescia, Meldola, Milan, Modena, Ravenna, Roma, Terni, Torino
2017-10-31
Recruiting
Turning Point Therapeutics, Inc.
Phase 1/2
500
Milan, Palermo, Pordenone, Ravenna, Reggio Emilia, Roma, Terni
2017-03-07
Active, closed
Hoffmann-La Roche
Phase 1/2
940
Ravenna, Milan, Rozzano
2017-02-21
Active, closed
Acerta Pharma BV
Phase 3
533
Bologna, Cagliari, Cona, Florence, Meldola, Milan, Modena, Ravenna
2015-07-28
Active, closed
Acerta Pharma BV
Phase 3
535
Alessandria, Aviano, Brescia, Florence, Meldola, Milan, Parma, Ravenna
2015-06-26
Active, closed
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
NCT02319837Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
DrugsLupron·Eligard·Leuprorelin·Xtandi
Pfizer
Phase 3
1,068
Roma, Cremona, Faenza RA, Lugo RA, Meldola (FC), Naples, Orbassano (TO), Ravenna
2014-12-17
Active, closed
Fondazione Italiana Linfomi - ETS
Phase 3
128
Milan, Ravenna, Candiolo, Castelfranco Veneto, Terni, Busto Arsizio, Alessandria, Ascoli Piceno
2014-05
Recruiting
Patient Retrospective Outcomes (PRO)
NCT01550575Chronic Pain
Boston Scientific Corporation
Observational
15,000
Alessandria, Naples, Ravenna, Rionero in Vulture, Rome, Verona
2012-04-03
Active, closed
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
1,649
Aviano, Ravenna, Turin
1998-10
Rows per page Showing 1–119 of 119
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-italy/city/ravenna

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,791 studies in total at the last sync on 11 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 119 of those studies with a site in Ravenna.

How many clinical trials are recruiting in Ravenna?

64 of the 119 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 55 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Ravenna), 119 studies
PhaseStudiesRecruitingShare
Phase 3501942%
Phase 2231519.3%
Phase 1/2181215.1%
Observational12810.1%
Not applicable645%
Phase 1625%
Phase 2/3443.4%

Most active sponsors

Lead sponsors with the most studies (Ravenna)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC91
Hoffmann-La Roche72
Bristol-Myers Squibb66
AstraZeneca54
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS55
Merck Sharp & Dohme LLC44
Acerta Pharma BV30
BeOne Medicines30
CatalYm GmbH33
European Organisation for Research and Treatment of Cancer - EORTC31
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.